Medication Assisted Treatment Program Policies: Opinions of People in Treatment
This study aims to understand factors that help individuals enter and stay in MAT from the perspective of those in recovery. The patient perspective is vital in efforts to improve care delivery and best support individuals in treatment.METHODS: Survey development was driven by a review of current peer-reviewed literature plus information gained through 3 semi-structured interviews and follow-up discussions with 5 individuals who have lived experience in MAT, termed Participant Advisors. Survey questions focused in part on MAT participants' opinions relating to program policies such as drug testing, relapse protocols, durat...
Source: Primary Care - August 28, 2023 Category: Primary Care Authors: Martha Carter Jennifer Boyd Trey Bennett Adam Baus Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
